Perron P - Search Results

1

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.

de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ; Simvastatin in Children Study Group. de Jongh S, et al. Among authors: perron p. Circulation. 2002 Oct 22;106(17):2231-7. doi: 10.1161/01.cir.0000035247.42888.82. Circulation. 2002. PMID: 12390953 Clinical Trial.

2

Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene.

Gaudet D, Vohl MC, Perron P, Tremblay G, Gagné C, Lesiège D, Bergeron J, Moorjani S, Després JP. Gaudet D, et al. Among authors: perron p. Circulation. 1998 Mar 10;97(9):871-7. doi: 10.1161/01.cir.97.9.871. Circulation. 1998. PMID: 9521335

3

Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia.

Bouhali T, Brisson D, St-Pierre J, Tremblay G, Perron P, Laprise C, Vohl MC, Vissers MN, Hutten BA, Després JP, Kastelein JJP, Gaudet D. Bouhali T, et al. Among authors: perron p. Atherosclerosis. 2008 Jan;196(1):262-269. doi: 10.1016/j.atherosclerosis.2006.10.035. Epub 2006 Nov 22. Atherosclerosis. 2008. PMID: 17123536

4

Ethical issues in molecular screening for heterozygous familial hypercholesterolemia: the complexity of dealing with genetic susceptibility to coronary artery disease.

Gaudet D, Gagné C, Perron P, Couture P, Tonstad S. Gaudet D, et al. Among authors: perron p. Community Genet. 1999;2(1):2-8. doi: 10.1159/000016176. Community Genet. 1999. PMID: 11658106 No abstract available.

5

Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men.

Gaudet D, Vohl MC, Couture P, Moorjani S, Tremblay G, Perron P, Gagné C, Després JP. Gaudet D, et al. Among authors: perron p. Atherosclerosis. 1999 Mar;143(1):153-61. doi: 10.1016/s0021-9150(98)00268-8. Atherosclerosis. 1999. PMID: 10208490

6

Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia.

Vohl MC, Gaudet D, Moorjani S, Tremblay G, Perron P, Gagné C, Lesiège D, Bergeron J, Lupien PJ, Després JP. Vohl MC, et al. Among authors: perron p. Eur J Clin Invest. 1997 May;27(5):366-73. doi: 10.1046/j.1365-2362.1997.1250669.x. Eur J Clin Invest. 1997. PMID: 9179542

7

[Familial hypercholesterolemia in eastern Quebec: a public health problem? The experience of the hyperlipidemia clinic of Chicoutimi].

Gaudet D, Tremblay G, Perron P, Gagné C, Ouadahi Y, Moorjani S. Gaudet D, et al. Among authors: perron p. Union Med Can. 1995 Sep;124(2):54-60. Union Med Can. 1995. PMID: 8846258 French. No abstract available.

8

Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec.

Vohl MC, Moorjani S, Roy M, Gaudet D, Torres AL, Minnich A, Gagné C, Tremblay G, Lambert M, Bergeron J, Couture P, Perron P, Blaichman S, Brun LD, Davignon J, Lupien PJ, Després JP. Vohl MC, et al. Among authors: perron p. Clin Genet. 1997 Jul;52(1):1-6. doi: 10.1111/j.1399-0004.1997.tb02506.x. Clin Genet. 1997. PMID: 9272705

9

Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians.

Gaudet D, Vohl MC, Julien P, Tremblay G, Perron P, Gagné C, Bergeron J, Moorjani S, Després JP. Gaudet D, et al. Among authors: perron p. Am J Cardiol. 1998 Aug 1;82(3):299-305. doi: 10.1016/s0002-9149(98)00328-2. Am J Cardiol. 1998. PMID: 9708657

10

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

156 results

Search Page